Immunomedics' agent to be reviewed by US panel:
This article was originally published in Clinica
Executive Summary
The US FDA's medical imaging drugs advisory committee will review Immunomedics' product licence application for Immuno-4, a murine MAb fragment against carcinoembryonic antigen (CEA), on February 16th.